Safety, tolerability and experience
Clinical trials and extensive real-world experience demonstrated that FLUAD Quad has a systemic safety profile similar to that of other seasonal flu vaccines.1,2
Vaccination with FLUAD Quad is associated with more local reactions, but a similar level of systemic reactions to other seasonal flu vaccines.
These are usually mild to moderate and typically resolve within 1–3 days.1,3
Approved in New Zealand, Australia, UK, EU, US and other countries.4
186 million doses* have been distributed worldwide.4
* Dose count includes doses distributed globally as of May 2021 and includes both FLUAD Trivalent and FLUAD Quad.
Reference: 1. Seqirus NZ. FLUAD Quad Data Sheet. Seqirus (NZ) Ltd. November 2022. 2. Frey SE, et al. Vaccine. 2014;32:5027-5034. 3. Beyer WEP et al. Vaccine 29 (2011) 5785– 5792. 4. Data on file. Seqirus Inc; 2021.